Wednesday, 16 April 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 16 April 2025
News

TGA issues drug safety warning

Posted 10 April 2025 AM

The TGA has announced that new safety information will be added to all isotretinoin products, a prescription medicine for severe cystic acne, after 117 cases of "serious" psychiatric adverse events were identified in Australia.

Isotretonoin was orginally sold as Roche's Roaccutane and has been since genericised under the brand names: Apo-isotretinoin, Isotretinoin Gx, Isotretinoin Lupin and Isotreinoin-wgr.

To see the whole article, please login

Popular

Local pharma slashes workforce
TGA issues drug safety warning
Who has industry's best reputation?
MA hires senior Health Dept exec
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (13)

Clinical & Medical, R&D (4)

Regulatory, Pharmacovigilance & QA (6)

Other (16)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home